Kymera Therapeutics KYMR Finance Lease Liability, Current
Finance Lease Liability, Current at other companies
Other financials
Where this comes from
Reported directly by Kymera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:FinanceLeaseLiabilityCurrent.
The official record: Kymera Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kymera Therapeutics's finance lease liability, current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kymera Therapeutics's finance lease liability, current?
- Kymera Therapeutics (KYMR) reported finance lease liability, current of $1.7M in Q1 2026.
- How has Kymera Therapeutics's finance lease liability, current changed year-over-year?
- Kymera Therapeutics's finance lease liability, current increased by 9.1% year-over-year, from $1.56M to $1.7M.
- What is the long-term trend for Kymera Therapeutics's finance lease liability, current?
- Over 5 years (2020 to 2025), Kymera Therapeutics's finance lease liability, current has grown at a 21.4% compound annual growth rate (CAGR), from $689K to $1.82M.
- What does finance lease liability, current mean?
- Finance lease liabilities (current) represent the portion of lease obligations that are due to be paid within the next twelve months. These obligations arise from long-term contracts where the company effectively controls the leased asset. This metric is critical for assessing near-term liquidity and cash flow requirements.